Bayesian design and analysis of active control clinical trials

Area of Science:

• Clinical Trials
• Biostatistics
• Bayesian Inference

Background:

• Active control trials compare experimental treatments (E) to effective controls (C) when placebo (P) comparison is unethical.
• Traditional trial designs focus on equivalence or non-inferiority, often involving arbitrary difference thresholds.
• Existing methods may lack flexibility in assessing treatment superiority and relative effectiveness.

Purpose of the Study:

• To propose and evaluate a Bayesian approach for designing and analyzing active control clinical trials.
• To provide posterior probabilities for treatment superiority (E vs. P) and relative efficacy (E vs. C).
• To offer a more flexible and less arbitrary framework compared to traditional frequentist methods.

Main Methods:

• Developed a Bayesian framework for active control trial design and analysis.
• Derived posterior probabilities for key comparative outcomes.
• Utilized logistic and proportional hazard models for approximations.
• Discussed the selection of appropriate prior distributions.

Main Results:

• The Bayesian approach yields probabilities for E being superior to P.
• Quantifies the probability that E is at least k% as good as C.
• Demonstrated the method's application using data from an unstable angina drug trial.
• Provided approximations for common statistical models.

Conclusions:

• The proposed Bayesian method offers a principled and flexible alternative for active control trials.
• It addresses limitations of traditional approaches by providing direct probability statements.
• This framework enhances the assessment of experimental treatments relative to active comparators and placebo.